ABPI response to human medicines regulations changes

Following a consultation, the Government has today announced changes to the Human Medicines Regulations, which will support the rollout of any COVID-19 vaccine.  

Companies have a huge sense of responsibility and urgency to create a safe and effective vaccine for COVID-19.  Dr Sheuli Porkess

In response, Dr Sheuli Porkess, Director of Research, Medical and Innovation at the ABPI said: 

“Companies have a huge sense of responsibility and urgency to create a safe and effective vaccine for COVID-19.

“When there is a breakthrough, the public can be confident it will have been through the most rigorous safety procedures and extensive trials in thousands of people.

“Given the scale of the issue, it’s important that the Government prepares in the best way possible so that any vaccine developed can reach patients when it is ready, and we are committed to working together to get this right.”

TAGS
  • COVID 19

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.